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Microglial activation decreases retention of the
protease inhibitor saquinavir: implications for HIV
treatment
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Abstract
Background: Active HIV infection within the central nervous system (CNS) is confined primarily to microglia. The
glial cell compartment acts as a viral reservoir behind the blood-brain barrier. It provides an additional roadblock to
effective pharmacological treatment via expression of multiple drug efflux transporters, including P-glycoprotein.
HIV/AIDS patients frequently suffer bacterial and viral co-infections, leading to deregulation of glial cell function and
release of pro-inflammatory mediators including cytokines, chemokines, and nitric oxide.
Methods: To better define the role of inflammation in decreased HIV drug accumulation into CNS targets,
accumulation of the antiretroviral saquinavir was examined in purified cultures of rodent microglia exposed to the
prototypical inflammatory mediator lipopolysaccharide (LPS).
Results: [3H]-Saquinavir accumulation by microglia was rapid, and was increased up to two-fold in the presence of
the specific P-glycoprotein inhibitor, PSC833. After six or 24 hours of exposure to 10 ng/ml LPS, saquinavir
accumulation was decreased by up to 45%. LPS did not directly inhibit saquinavir transport, and did not affect
P-glycoprotein protein expression. LPS exposure did not alter RNA and/or protein expression of other transporters
including multidrug resistance-associated protein 1 and several solute carrier uptake transporters.
Conclusions: The decrease in saquinavir accumulation in microglia following treatment with LPS is likely multi-
factorial, since drug accumulation was attenuated by inhibitors of NF-κβ and the MEK1/2 pathway in the microglia
cell line HAPI, and in primary microglia cultures from toll-like receptor 4 deficient mice. These data provide new
pharmacological insights into why microglia act as a difficult-to-treat viral sanctuary site.
Keywords: Drug transporters, HIV, Inflammation, MEK1/2, Microglia, Multidrug resistance proteins, NF-kappa β,
P-glycoprotein, Saquinavir, Solute carrier uptake transporters, Toll-like receptor
Introduction
Microglia are increasingly implicated in the pathogenesis
of numerous neurodegenerative disorders including
Parkinson’s, Alzheimer’s, and lateral sclerosis [1]. The
evidence for a microglial component in the development
of dementia is particularly convincing in HIV/AIDS pa-
tients, as the primary site of CNS infection is within
resident microglia cells. Once infected, activated
microglia release a number of pro-inflammatory media-
tors that directly damage nearby neurons, and deregulate
normal brain parenchymal homeostasis through their
interaction with astrocytes and uninfected microglia [2].
Despite recent advances in antiretroviral (AR) therapies,
HIV-related neurological symptoms remain difficult to
treat and HIV-associated neurological impairment con-
tinues to be very high among patients who are now liv-
ing with a ‘chronic’ disorder [3].
One limitation of current HIV/AIDS drug regimens
continues to be the development of ‘pharmacological re-
sistance’ to currently available AR drugs. That is, high
levels of energy-dependent efflux drug transporters such
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as P-glycoprotein and multidrug resistance-associated
proteins (MRPs) in target cells prevent accumulation of
drugs to levels sufficient to provide a therapeutic effect
[4]. Clinically, lower amounts of protease inhibitors such
as saquinavir and ritonavir accumulate in peripheral viral
compartments such as blood mononuclear cells in HIV-
infected patients who demonstrate greater P-glycopro-
tein and MRP1 expression [5,6]. Using P-glycoprotein
knock-out mice, multiple laboratories have confirmed
that P-glycoprotein significantly limits brain accumula-
tion of saquinavir, and other protease inhibitors inclu-
ding indinavir and amprenavir at the level of the
blood-brain barrier (BBB) [7-10]. Previously, we have
demonstrated that cultured rat microglia also express
multiple drug transporters including P-glycoprotein [11],
Mrp1 [12], and Mrp4/5 [13]. These transporters are not
only present in significant quantities but are also func-
tionally active, able to transport a variety of known
anti-HIV medications including zidovudine, saquinavir,
ritonavir, indinavir and atazanavir [14-16].
In addition to HIV, AIDS patients frequently suffer
multiple bacterial and viral co-infections (for example,
CNS toxoplasmosis, cryptococcosis, and tuberculosis)
and are under a constant state of generalized brain
inflammation. This leads to deregulation of microglial
cell function and release of pro-inflammatory media-
tors (for example, IL1β; TNF-α), reactive oxygen spe-
cies, and viral proteins (gp120; tat), all shown to alter
transporter expression and/or function in multiple
cell types via complex, and often redundant, signaling
pathways [17-20]. In brain endothelial cells, TNF-α
induces Mdr1b promoter activity via nuclear trans-
location of the transcription factor NF-κβ [21]. Simi-
larly, changes in P-glycoprotein transport activity and
expression in isolated rat brain capillaries occurs
following activation of the toll-like receptor 4 (TLR4),
which in turn triggers a cascade of molecular signal-
ing events involving TNF-α, endothelin-1, nitric oxide
synthase and protein kinase C [22]. More recently,
Mrp1 expression in primary rat astrocytes was also
shown to be regulated by TNF-α (but not IL-6 or
IL-1β), via NF-κβ and c-Jun N-terminal kinase signal-
ing [23]. How then, a self-propelling cycle of inflam-
mation and consequent cellular dysfunction affects
expression and function of microglial drug trans-
porters, and how this might ultimately affect brain
AR drug exposure is unknown. To begin to answer
these questions we have examined how drug trans-
port is altered in microglial cells following treatment
with the prototypical inflammatory mediator lipopo-
lysacharride (LPS). We show that LPS exposure re-
duces cellular accumulation of the protease inhibitor
saquinavir and examine possible mechanisms under-
lying this effect.
Methods and materials
Materials
Saquinavir was kindly provided from Roche Products Inc.
(Hertfordshire, UK). [3H]saquinavir (58 Ci/mmol) was syn-
thesized by Amersham (Piscataway, NJ, USA). MK571 was
obtained from Biomol (Plymouth Meeting, PA, USA). The
monoclonal antibodies MRPr1 and C219 were purchased
from Kamiya Biomedical (Seattle, WA, USA), and Signet
(Dedham, MA, USA), respectively. 2-(N,N-diethylamino)-
diazenolate-2-oxide (DEA NONOate) was purchased from
Alexis Biochemicals (Plymouth Meeting, PA, USA). [N-(3-
Aminomethyl)benzylacetamidine] (1400W), bisindolylma
leimide I (BIM), 1,4-Diamino-2,3-dicyano-1,4-bis(2-ami
nophenylthio)butadiene (U0126), diphenyleneiodonium
(DPI), endothelin-1 (ET-1), [4-(4-Fluorophenyl)-2-(4-me-
thylsulfinylphenyl)-5-(4-pyridyl)1H-imidadole] (SB203580);
4-hydroxy-2,2,6,6-tetramethylpiperidene-1-oxyl (Tempol),
NG-monomehtyl-L-arginine monoacetate (L-NMMA),
interleukin1beta (IL-1β), LPS (E.Coli 0111:B4); phorbol-
12-myristate-13-acetate (PMA), 5-pregnen-3β-ol-20-one-
16α-carbonitrile (PCN), prostaglandin E2 (PGE2), 1,9-
pyrazoloanthrone (JNK II), NF-κβ inhibitor peptide
(SN50), tissue inhibitor of metalloproteinase-3 (TIMP3),
tumor necrosis factor-alpha (TNF-α), type I IL-1β receptor
antagonist (IL-1β RA), wortmannin, and antibodies against
IL1-β and TNF-α were all purchased from Calbiochem
(La Jolla, CA, USA). Fucoidan was obtained from Sigma
(St Louis, MO, USA). All tissue culture reagents were
purchased from Invitrogen (Carlsbad, CA, USA) unless
otherwise indicated.
Animals
Timed pregnant (gestation E14) Wistar and Fisher rats
were purchased from Charles River Laboratories (Wil-
mington, MA, USA). Timed Pregnant (gestation E14)
C3HeB/FeJ (TLR4+/+), and C3H/HeJ (TLR4-/-) mice
were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). The C3H/HeJ strain contains a
spontaneous mutation in the TLR4 gene making these
mice deficient in TLR4-mediated responses, where they
are resistant to endotoxins such as LPS. All animals were
maintained in a strict pathogen-free environment. All
studies were approved by the National Institutes of En-
vironmental Health Sciences institutional review board
and adhered to NIH guidelines for the care and handling
of experimental animals.
Primary cultures of microglia
Primary microglia-enriched cultures were prepared from
whole brains of one to two day-old mice and rats as de-
scribed previously, with modifications [24]. Following
decapitation, whole brains were removed, and brain tis-
sue triturated after meninges and blood vessel removal.
Cells (5×107) were seeded in complete medium (DMEM
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containing 10% fetal bovine serum, penicillin (50 U/ml)/
streptomycin (50 mg/ml), L-glutamine (2 mM), non-
essential amino acids (100 μM), and sodium pyruvate
(1 mM), pH 7.2), in 175 cm2 culture flasks pre-coated with
Poly-D-lysine (Sigma-Aldrich, St Louis, MO, USA).
Medium was changed at 24 hours and on day seven. After
14 days, a confluent monolayer of mixed glial cells was
obtained with microglia lightly adhered to the astrocyte
layer. Essentially pure microglia cultures (> 98% as deter-
mined by IBA-1 staining) were then obtained from shak-
ing the lightly adherent microglia, and seeding the cells in
24-well plates for subsequent assays. Cells were used for
subsequent experiments at 24 hours post-shaking.
Microglia cell line
The continuous rat microglia cell line HAPI was origin-
ally isolated from mixed glial cultures prepared from
three day-old rat pups, and was a generous gift of Dr
James R Connor (Hershey Medical Center, Pennsylvania
State University, Hershey, PA, USA). The cells exhibit
prototypical microglia type behavior including the ability
to phagocytose, and to release TNF-α and NO upon
stimulation with LPS [25]. The cell line was maintained
at 37°C in DMEM supplemented with 10% FBS, 50 U/mL
penicillin and 50 μg/mL streptomycin in a humidified
incubator with 5% CO2/95% air. Cells were passaged twice
weekly using 0.25% trypsin containing EDTA. Passages six
through twelve were used for all studies.
Microglial incubation with LPS and signal transduction
activators and inhibitors
Primary cultures of microglia and HAPI cells were
plated in 2-well dishes for transport, nitrite and TNF-α
assays or 25 cm2 flasks for immunoblotting and PCR
assays, and incubated with 1 to 10 ng/ml LPS for 6 or
24 hours in MEM containing 2% FBS. Similar to LPS,
the effects of various well-characterized inflammatory
mediators/activators on saquinavir accumulation were
examined. In this system, a decrease in saquinavir accu-
mulation can represent either a decrease in the uptake
of the compound, or an increase in the efflux of the
compound. Concentrations and duration of treatment
for the various pathway activators and inhibitors were
consistent with previously published studies undertaken
in microglia (and/or other cell types such as macro-
phages and brain capillaries), or based on manufacturer’s
recommendations [1,22,26-28]. None of the activators or
inhibitors tested in the presence or absence of LPS
showed significant toxicity, as measured by the MTT
assay. The following activators were tested: adenylate
cyclase regulator PGE2 (1 μM), cytokines TNF-α (10 ng/ml)
and IL-1β (10 ng/ml); the nitric oxide donor DEA
NONOate (1, 10, 25 μM); rat PXR nuclear hormone
receptor activator PCN (1 μM), protein kinase C activator
PMA (1 μM), and the thromboxane A2 activator ET-1
(1 μM). For studies examining signal transduction path-
way inhibition, cells were pre-incubated with pathway spe-
cific inhibitors for 30 minutes prior to the addition of LPS
(10 ng/ml). Inhibitors examined were: the scavenger re-
ceptor inhibitor fucoidan (50 ng/ml); free radical scaven-
ger Tempol (20 μM); an IL-1β receptor antagonist
(10 μg/ml); c-Jun N-terminal kinase inhibitor JNK II
(10 μM); MAP kinase (MEK)-1 and -2 inhibitor, U0126
(10 μM); NADPH oxidase inhibitor DPI (10 nM); nitric
oxide synthase inhibitor 1400W (5 μM); NF-κβ peptide
inhibitor, SN50 (10 μM); p38 MAP kinase inhibitor
SB203580 (10 μM); phosphatidylinositol 3-kinase (PI3-
kinase) inhibitor wortmannin (1 μM); protein kinase C in-
hibitor BIM (25 nM); metalloproteinase inhibitor TIMP3
(10 ng/ml); and antibodies against TNF-α (0.5 μg/ml),
IL-1β (0.5 μg/ml), toll-like receptor 2 (anti-TLR2, 1 μg/ml)
and toll-like receptor 4 (anti-TLR4, 1 μg/ml). At the
conclusion of the incubation period with either the activa-
tion or inhibition compounds, cells were immediately
assayed for transport, nitrite, TNF-α or protein content, as
described in subsequent sections.
[3H]saquinavir transport studies
Accumulation of [3H]saquinavir (50 nM) was measured
in treated and untreated primary cultures of microglia
and HAPI cells as described previously, with modifica-
tions [14]. At the conclusion of the pathway activator/
inhibitor incubation, cells were washed once and pre-
conditioned for 30 minutes at 37°C with transport
medium (Earle’s balanced salt solution (EBSS), con-
taining 1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4,
138 mM NaCl, 1.0 mM Na2HPO4, 5.5 mM D-glucose
and 20 mM HEPES, pH 7.4). Cells were then incubated
for the desired time with transport medium containing
[3H]saquinavir (50 nM) with or without various trans-
port inhibitors. At completion of the accumulation
period, the transport medium was removed by aspiration
and accumulation was terminated by adding ice-cold
EBSS. Cells were solubilized for 30 minutes with 1 N
NaOH and then transferred to scintillation vials con-
taining 2 N HCl and scintillation cocktail (Beckman
Coulter; Fuller, CA, USA). Cellular incorporation of the
radiolabeled probe was measured using liquid scintilla-
tion counting. The sample counts in each well were
standardized to the amount of cell protein (mg/ml)
present, as determined by the Bradford colorimetric
method (Bio-Rad, Hercules, CA, USA) with BSA
(Sigma-Aldrich, St Louis, MO, USA) as the standard.
Nitrite measurement
Nitric oxide production and release by primary cultures
of microglia and HAPI cells were determined by meas-
urement of nitrite levels using a colorimetric method
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with Griess reagent (0.1% N-[1-naphthyl] ethylenedi-
amine dihydrochloride, 1% sulfanilamide, and 2.5%
H3PO4) as described previously [24]. Briefly, cells were
seeded in 24-multiwell plates and incubated with and
without LPS and/or various signal pathway inhibitors/
activators for 24 hours. At the end of the incubation
period, culture supernatants were mixed with equal
volumes of Griess reagent, incubated in the dark for 10
minutes and the absorbance (540 nm) was measured
with a UV MAX kinetic microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The absolute nitrite con-
centrations were determined from an eight-point sodium
nitrite standard curve. The lower limit of detection of
the assay was approximately 1.5 μM.
TNF-α determination
Cells were seeded in 24-multiwell plates and incubated
with and without LPS and/or various signal pathway in-
hibitors/activators for 24 hours. At the end of the incu-
bation period, the production and release of TNF-α into
the culture medium by primary cultures of microglia or
HAPI cells was measured with a commercially available
enzyme-linked immunosorbent assay (ELISA) kit from
R&D Systems (Minneapolis, MN, USA), according to
the manufacturer’s instructions. The absorbance (450
nm) was measured with a UV MAX kinetic microplate
reader (Molecular Devices, Sunnyvale, CA, USA), using
a 570 nm wavelength correction.
RT-PCR analysis
RNA expression of several transporters was measured by
reverse transcriptase polymerase chain reaction (RT-
PCR). RNA (3 μg) from microglia (HAPI) was dried
down, and resuspended in 5 μL of RNAse-free water.
The RNA was reverse transcribed from an oligo-dT pri-
mer using Omniscript (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Following
reverse transcription, 1.5 μL of the 20 μL reaction was
used in a polymerase chain reaction (1X reaction buffer
(Promega, Madison, WI, USA), 0.2 mM dNTPs, 0.25 μM
each primer (Table 1), 0.25 μL Taq polymerase (Promega,
Madison, WI, USA). Cycling parameters were one cycle at
95°C for five minutes, followed by 35 cycles of 94°C
(20 seconds), 55°C (30 seconds), 72°C (30 seconds), and a
final extension at 72°C for seven minutes. RT-PCR
products were analyzed by agarose gel electrophoresis.
GAPDH was used as an endogenous control. Primers for
GAPDH were acquired from PE Applied Biosystems
(Foster City, CA, USA).
Immunoblotting
Crude membrane proteins were obtained from treated
and untreated HAPI microglia. Following treatment,
cells were washed three times with ice-cold Hanks bal-
anced salt solution (HBSS) buffer and lysed for 10 mi-
nutes at 4°C in Cell Lytic™ M mammalian cell lysis/
extraction reagent (Sigma-Aldrich, St Louis, MO, USA)
containing Complete protease inhibitor cocktail (Roche,
Indianapolis, IN, USA). The cell lysate was homogenized
using a hand-held polytron, and the resulting cell sus-
pension was centrifuged for 10 minutes at 4°C (1,000xg)
to remove cellular debris. The supernatant was collected
and centrifuged at 20,000xg for 30 minutes, followed by
100,000xg for an additional one hour. The resulting
membrane pellet was resuspended in suspension buffer
and frozen at −80°C until use.
For P-glycoprotein studies, crude membrane samples
were separated on NuPage 7% sodium-acetate gels (Invit-
rogen, Grand Island, NY, USA) using a Bio-Rad minigel
system (Bio-Rad, Hercules, CA, USA), and transferred
electrophoretically to polyvinylidene difluoride (PVDF)
membranes. The membranes were blocked for at least one
hour and incubated overnight with the P-glycoprotein
antibody C219 (1:100) in SuperBlock blocking buffer in
TBS containing 0.5% Surfact-Amps 20 (TBS-T) (Pierce,
Rockford, IL, USA) at 4°C. Following three washes (five
minutes each) with TBS-T, the membranes were incubated
at room temperature for two hours in the presence of
anti-mouse (1:5,000) horseradish peroxidase-linked sec-
ondary antibody (Sigma-Aldrich, St. Louis, MO, USA) in
TBS-T. The epitope of C219 has been mapped to the
amino acid sequences VQEALD and VQAALD in the
C-terminal and N-terminal halves of P-glycoprotein,
respectively [29]. Proteins were visualized using enhanced
Table 1 PCR Primers
Gene Forward Primer Reverse Primer
Slc22a1 TCTGGCTACAGGAGAACGACGGCCA TGCTCCATTATCCTGACAGCTCGCGT
Slc22a2 TCGAAACAGAGGAGGATTGTGGGAATA GAGAGGTGTTTCCCATTGCACTTAGCCAC
Slc22a6 TATGTGGGCACCTTGATTGGC AGGGTGAGGTCCAGCCTTCCT
Slc22a8 ATCTCATCAACATCTATTGGG AGGGCCTTTGAGTATTTTCCA
Slco1a1 TATGGAGGACAAGCCAGAGAG AGAGGTGGTTAATCCAGCAAC
Slco1a2 CACAGAAAAAAGGCCAAGGAA TAAGGAAAGACAGAAGGTACT
Slco1a5 CACAGAGAAAAAGCCAAAGAG AGAGGCAGTTAAGCCGGCAAC
Slc22a, solute carrier family 22; Slco, solute carrier organic anion family.
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chemiluminescence according to the manufacturer’s in-
structions (Pierce, Rockford, IL, USA). Images were cap-
tured by a Bio-Rad Gel Doc XR imaging system (Bio-Rad,
Hercules, CA, USA) using the Manufacturer’s Quantity
One software (version 4.6). MRP1 immunoblotting studies
were conducted in a similar manner except that crude
membrane samples were separated on NuPage 4-12%
Bis-Tris gels (Invitrogen, Grand Island, NY, USA), and
resulting membranes were probed first with the MRP1
antibody MRPr1 (1:100), followed by an anti-rat secondary
(1:5,000). The MRP1 mAb MRPr1 was raised against a
bacterial fusion protein containing amino acids 194 to 360
of human MRP1 [30] and its epitope was subsequently
localized to amino acids 238 to 247 [31]. Equivalent pro-
tein loading of all gels was verified using GAPDH as a
loading control.
Data analysis
[3H]saquinavir accumulation values are expressed as
pmol/mg protein and are presented as mean ± standard
error (SE) from a minimum of three separate experi-
ments. In an individual experiment, each data point
represents a minimum of triplicate trials. For multiple
comparisons, the test of repeated measures of analysis of
variance (ANOVA) and the Bonferroni post hoc analysis
was used. A value of P < 0.05 was considered statistically
significant.
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Figure 1 Accumulation of saquinavir by HAPI microglia in the
presence of the P-glycoprotein inhibitor PSC833. (A) [3H]
saquinavir (50 nM) accumulation by HAPI cells was measured in the
presence (closed circles) or absence (open circles) of PSC833 (5 μM)
at 0.5, 1, 2, 5, 10, 30, 60 and 120 minutes, at 37°C. (B) [3H]saquinavir
(50 nM) accumulation by HAPI microglia increased significantly, in a
dose dependent manner, in the presence of excess unlabelled
saquinavir (1 to 10 μM). Each data point represents mean ± SE of at
least three separate experiments with three replicates included per
experiment; *P < 0.05, significantly different from control.
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Figure 2 Effect of LPS on [3H]saquinavir accumulation and
inflammatory mediator release by HAPI microglia cells. (A)
Following 24 hours of incubation at increasing LPS concentrations
(1 to 10 ng/ml) (black bars), [3H]saquinavir (50 nM) accumulation in
HAPI cells was determined at one hour (37°C) using scintillation
counting. The accumulation was dose-dependent at concentrations
higher than 2.5 ng/ml LPS. (B) Accumulation of [3H]saquinavir
(50 nM) for one hour following addition of LPS into the transport
buffer. Each data point represents mean ± SE of at least three
separate experiments with three replicates included per experiment;
*P < 0.05, significantly different from control.
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Results
[3H]saquinavir accumulation in HAPI microglia is P-
glycoprotein dependent
Accumulation of 50 nM [3H]saquinavir by HAPI micro-
glia was initially rapid, reaching steady-state within 60
minutes (Figure 1A). All subsequent transport studies
were performed at this time point. The potent and specific
P-glycoprotein inhibitor PSC833 (5 μM), increased accu-
mulation significantly, and this increase was seen at times
as early as 30 seconds. This result is consistent with
P-glycoprotein mediating saquinavir efflux from the cells.
Addition of excess cold saquinavir to the transport buffer
also increased [3H]saquinavir accumulation, significantly
suggesting saturation of transport (Figure 1B). Similar
results were previously reported for P-glycoprotein in
another cultured microglia cell line, MLS-9 [11,15].
LPS reduces [3H]saquinavir accumulation
Exposing HAPI cells to 10 ng/ml LPS for six hours
significantly reduced saquinavir accumulation by 25 ±
2.5% (P < 0.05). With 24 hours of exposure, 1 to 10 ng/
ml LPS reduced accumulation in a concentration-
dependent manner, with 10 ng/ml reducing accumula-
tion by 43% (Figure 2A). LPS did not directly affect
saquinavir accumulation, since including 1 or 10 ng/ml
LPS in the transport medium did not affect saquinavir
accumulation during the 60 minute assay (Figure 2B).
Furthermore, viability of the cells (expressed as percent
untreated control) following 24 hours of incubation with
10 ng/ml LPS (92 ± 6%) was not significantly different
from that of untreated cells (100 ± 3%).
To determine whether the change in saquinavir accu-
mulation with LPS exposure was due to altered P-
glycoprotein function, we measured drug accumulation
in the presence and absence of 5 μM PSC833 in control
and LPS-treated (24 hours) cells. As expected, total
saquinavir accumulation decreased in the presence of 10
ng/ml LPS and increased in the presence of PSC833
(5 μM) in both control cells (+77%) and in LPS-exposed
cells (+58%; Figure 3A). The PSC833-sensitive compo-
nent of saquinavir accumulation increased significantly
in the LPS-treated cells (+31%), suggesting that in-
creased P-glycoprotein mediated transport (Figure 3B).
We found a similar trend in cells exposed to 10 ng/ml
LPS for six hours (data not shown). Importantly, follow-
ing exposure to 1 to 10 ng/ml LPS, we observed no
changes in P-glycoprotein expression at the protein level
(Figure 4A).
Other transporters do not contribute to decreased
saquinavir accumulation
We previously demonstrated that saquinavir interacts with
a second efflux transporter in microglia, namely Mrp1
[14]. We used the Mrp inhibitor MK571 to measure the
Mrp-mediated component of transport in the HAPI cells.
In contrast to P-glycoprotein, there was no significant
change in the Mrp sensitive transport component in HAPI
microglia following LPS exposure for six hours (−9 ± 3%)
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Figure 3 Interactions with P-glycoprotein in HAPI microglia only partially explain the LPS-mediated changes in saquinavir
accumulation. (A) Following 24 hours LPS incubation (10 ng/ml), accumulation of [3H]saquinavir (50 μM) at one hour (37°C) was measured in
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or 24 hours (−14 ± 14%). Protein expression (Figure 4B)
was also unchanged at these time points.
In addition to P-glycoprotein and multiple MRP iso-
forms, saquinavir and other AR compounds interact
with multiple members of the solute carrier (SLC) trans-
porter family, including the human organic anion poly-
peptide (OATP) transporters OATP1B1, 1B3 and 2B1
[32,33], and the human organic cation transporters
OCT1 and 2 [34]. At present, the expression and func-
tion of SLC transporters in microglia is unknown. We
determined whether expression of well-characterized
anionic and cationic SLC transporters could be detected
in HAPI microglia at the transcriptional level. Using
RT-PCR, we could not detect transcripts of Slco1a1, 1a2,
or 1a5, which encode protein for Oatp1a1, 1a2 and -1a5,
respectively. Slc22a6, 22a8 and 22a1 genes which encode
for Oat1, 3, and Oct1, respectively, were also undetected
in HAPI cells. The Slc22a2 gene transcript encoding for
Oct2 was detected in HAPI cells, but was unchanged in
the presence of 10 ng/ml LPS (data not shown).
Multiple molecular pathways regulate P-glycoprotein in
HAPI microglia exposed to LPS
Exposure of microglia to LPS produces a robust pro-
inflammatory response, including the production and re-
lease of cytokines, chemokines, reactive oxygen species
and other pro-inflammatory mediators. This response is
largely mediated through multiple cell surface receptors
including TLR-2, TLR-4 and multiple scavenger recep-
tors [35]. The released inflammatory mediators can then
interact with additional cell surface receptors and intra-
cellular pathways, initiating new molecular cascades and
inciting a self-propelling cycle of cellular activation. Pre-
treatment of HAPI microglia with inhibitors of scaven-
ger receptors and NADPH oxidase (that is, fucoidan and
DPI, respectively) did not attenuate the LPS-related de-
crease in saquinavir accumulation mediated by LPS
(Table 2). However, decreases in saquinavir accumula-
tion by HAPI microglia were partially attenuated by
antibodies to TLR2 and TLR4 (Table 2). To confirm that
LPS effects were mediated by TLR-4, we used primary
cultures of microglia from wild-type and TLR4 deficient
mice. In wild-type cultures, exposure to 10 ng/ml
LPS significantly decreased saquinavir accumulation
(Figure 5A). However, this decrease was small, averaging
only 16% of total accumulation. Importantly, in micro-
glia from TLR-4 deficient mice, LPS exposure did not
alter saquinavir accumulation. We repeated the basic
LPS exposure experiment in primary microglia from
Wistar rats and Fisher rats and found that LPS exposure
reduced saquinavir accumulation by 45% and 61%, re-
spectively (Figures 5B and C). These effects were similar
to that seen in the rat-derived HAPI microglia cell line
(approximately 64% of control), and considerable higher
P-gp
24 hr
6 hr P-gp
g
A
GAPDH
GAPDH
6 hr
24 hr
Mrp124 hr
Mrp16 hr
1 40 40 40 40 40
10 10 10 10 10 10 g
GAPDH6 hr
24 hr GAPDH
B
Figure 4 Protein expression of P-glycoprotein and Mrp1 in
HAPI cells following 6 or 24 hour LPS incubation. (A) HAPI
microglia were incubated for 6 or 24 hours in the presence of
increasing concentrations of LPS (1 to 10 ng/ml). At the end of the
incubation period, crude membrane fractions from the cell lysates or
from rat kidney brush border membranes (positive P-glycoprotein
control) were prepared as indicated in the text, and immunoblotting
of P-glycoprotein was performed. The proteins (1 or 40 μg each)
were separated on NuPage 7% sodium-acetate gels, transferred to
polyvinylidene difluoride membranes electrophoretically and
incubated with a P-glycoprotein monoclonal antibody, C219 (1:100),
followed by an anti-mouse HRPO-secondary (1:1,000). (B)
Immunoblotting of Mrp1 in HAPI microglia treated for 6 or 24 hours
with increasing concentrations of LPS (1 to 10 ng/ml) was
undertaken in a similar manner to P-glycoprotein except that the
proteins (10 μg) were separated on NuPage 4 to 12% Bis-Tris gels,
and incubated with a Mrp1 monoclonal antibody, MRPr1 (1:100),
followed by an anti-rat HRPO-secondary (1:1,000). Whole rat kidney
lysate (10 μg) was used as a positive Mrp1 control. Representative
immunoblots are shown.
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than that observed in the mouse, suggesting species dif-
ferences in LPS sensitivity. Nonetheless, the decrease in
saquinavir accumulation by LPS observed in the TLR4
WT mice was completely abrogated in the TLR4 defi-
cient mice (TLR4−/−).
Following LPS exposure, primary microglia extrude
pro-inflammatory mediators such as TNF-α, IL-1β and
NO [35]. Following 24 hours exposure to LPS, HAPI
microglia showed a concentration-dependent increase
in cellular extrusion of TNF-α (Figure 6A) and NO
(Figure 6B). Interestingly, exposure of HAPI microglia to
exogenously applied TNF-α and IL-1β, or NO generated
by the use of the NO donor DEA NONOate did not
alter saquinavir accumulation (Table 3). Pre-incubation
of HAPI with inhibitors targeted against the cytokines
themselves (anti-TNF-α, anti-IL-1β), or molecular path-
ways involved in up- or downstream signaling events for
the cytokines (IL-1β receptor antagonist, TIMP3) or NO
synthetase (1400W and L-NMMA) also did not alter the
ability of the cells to accumulate saquinavir (Table 2).
We further screened HAPI cells directly with a num-
ber of other well-characterized inflammatory mediators
known to be involved in microglial signaling ([36-38])
including the rat nuclear receptor PXR activator PCN
(1 μM), the thromboxane A2 activator ET-1 (1 μM), ad-
enylate cyclase regulator PGE2 (1 μM), and the protein
kinase C activator PMA (1 μM) [Table 3]. None of these
activators affected saquinavir accumulation. In addition,
cell permeable chemical inhibitors known to specifically
inhibit intracellular molecular pathways that function
within microglia such as multiple kinase pathways
([36-39]) were also tested. Full inhibition of the LPS-
induced decrease in saquinavir accumulation was found
for only two of the compounds tested. First, the NF-κβ
translocation inhibitor SN50 fully blocked the decreased
saquinavir accumulation mediated by LPS (Figure 7A).
No effect was observed with an inactive SN50 control
peptide, SN50I. SN50 also significantly lowered levels of
TNF-α (Figure 7B) and nitrite (Figure 7C) release in
response to LPS, confirming a generalized decrease in
microglial activation. Second, the MEK1/2 inhibitor
U0126 also fully blocked the LPS-mediated effects on
saquinavir accumulation by the cells (Figure 8A and
TNF-α (Figure 8B) and nitrite (Figure 8C) release.
Conclusions
Here, we investigated how LPS-induced inflammation al-
ters the function of drug transporters in microglia, the
primary CNS target of HIV, using a clinically relevant
concentration (50 nM) of the antiretroviral medication
saquinavir as a prototypical probe substrate and the fol-
lowing model systems: a rat microglia cell line, HAPI,
and primary cultures of rat and mouse microglia. Fur-
thermore, we examined at a molecular level, what mech-
anisms may drive the observed changes in saquinavir
accumulation and retention by microglia following an
inflammatory LPS challenge. As noted in another rat
microglia cell line [14], accumulation of saquinavir into
HAPI microglia cells was rapid, reached a plateau by
one hour, and was increased significantly by a potent
P-glycoprotein inhibitor PSC833. In this model, an in-
crease in saquinavir accumulation in the presence of
Table 2 Effect of various signal transduction pathway inhibitors on [3H]saquinavir accumulation in microglia
Inhibitor Concentration Saquinavir transport (% control)
10 ng/ml LPSa Inhibitor alone LPS + Inhibitor
Anti-TLR2 1 μg/ml 62 ± 2 99 ± 3 b82 ± 2
Anti-TLR4 1 μg/ml 62 ± 2 99 ± 4 b75 ± 3
Fucoidan 50 ng/ml 67 ± 3 92 ± 5 57 ± 2
DPI 10 nM 63 ± 2 94 ± 9 64 ± 11
Tempol 20 μM 63 ± 2 88 ± 7 60 ± 3
IL-1β RA 10 μg/ml 73 ± 2 102 ± 4 77 ± 3
Anti-IL-1β 0.5 μg/ml 63 ± 3 91 ± 2 64 ± 2
Anti-TNF-α 0.5 μg/ml 63 ± 3 89 ± 2 64 ± 2
TIMP3 10 ng/ml 57 ± 4 97 ± 5 61 ± 2
1400 W 5 μM 61 ± 3 94 ± 3 70 ± 2
L-NMMA 10 μM 58 ± 3 98 ± 7 63 ± 2
BIM 25 nM 61 ± 4 92 ± 3 67 ± 6
Wortmannin 1 μM 70 ± 2 99 ± 6 68 ± 3
SB203580 10 μM 63 ± 2 93 ± 2 63 ± 3
JNKII 10 μM 66 ± 3 96 ± 2 64 ± 3
Pathway inhibitor acronyms defined in text. aP < 0.05 as compared to untreated controls. bP < 0.05 as compared to LPS alone and untreated controls
(partial inhibition).
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PSC833 provides an indirect measure of compound ef-
flux by the transporter. Following both short (6 hour)
and long term (24 hour) LPS exposure in microglia, the
overall accumulation of saquinavir decreased in a dose-
dependent manner, with significant decreases observed
at 24 hours at doses greater than 2.5 ng/ml LPS. Using
LPS in the presence and absence of the P-glycoprotein
inhibitor PSC833, the decrease in saquinavir accumula-
tion was only partially explained by increases in P-glyco
protein function, that is, by increased P-glycoprotein-
mediated efflux of compound from the intracellular
compartment to the outside of the cell. The remainder
of the unaccounted saquinavir transport surprisingly
could not be explained by increases in efflux or protein
expression of Mrp1, a transporter known to handle sa-
quinavir efficiently. Although less likely, a decrease in
potential uptake of saquinavir into the cells via de-
creased SLC uptake transporter expression/function was
also considered. Transcripts of seven well- characterized
SLC transporters, some already well known to interact
with ARs, were examined in the presence and absence of
LPS. With the exception of Slc22a2, none of these trans-
porters (at the transcriptional level) were expressed sig-
nificantly in HAPI microglia. Furthermore, Slc22a2
transcript levels in HAPI microglia were unchanged fol-
lowing LPS exposure. Therefore, it is unlikely that a
change in SLC uptake transporters explains the reduced
accumulation of saquinavir following LPS treatment.
While it was clear that LPS exposure decreased
accumulation of saquinavir significantly in microglia, at
least partially through a P-glycoprotein pathway, protein
levels of that transporter were unchanged. One
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Figure 5 Decreased saquinavir accumulation by HAPI microglia in the presence of LPS is attenuated in TLR4 deficient mice. (A) Primary
microglia were isolated from TLR wild-type (TLR4 WT) and TLR4 deficient (TLR4−/−) mice, as described. In primary microglia isolated from TLR4 WT
mice, incubation with 10 ng/ml LPS for 24 hours decreased saquinavir significantly, that is, by approximately 16%. This effect was attenuated in
microglia derived from the TLR4−/− deficient mice, where there was no difference between LPS-treated and untreated deficient mice or the
untreated WT mice. *P < 0.05, significantly different from untreated TLR WT controls. (B) Primary microglia derived from Wistar, and (C) Fisher rats
incubated with 10 ng/ml LPS for 24 hours at 37°C also showed a significant decrease in saquinavir accumulation at one hour. *P < 0.05,
significantly different from untreated control cells.
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explanation for this may be that transporter function
was altered by signaling pathways downstream of TLR4,
resulting in for example, transporter dephosphorylation,
deglycosylation, or tyrosine nitration. Indeed, activation
of NF-κβ in HT29 colon cancer cells decreases transport
function of another drug transporter, human MRP3, via
tyrosine nitration of the protein [40]. This suggests that
TLR4 signaling regulates microglial P-glycoprotein activ-
ity to some extent, which is consistent with the fact that
cytokines and NO are produced 6 to 24 hours later in
the microglial response to LPS but fail to impact
P-glycoprotein function/saquinavir accumulation in the
current study. The role of TLR4 in P-glycoprotein regu-
lation is particularly relevant to pharmacotherapy in
HIV, as there is increasing evidence that HIV proteins
may activate macrophages through a TLR4 dependent
pathway. In fact, a recent study shows that HIV1-Vpr
induces cytokine production from macrophages through
TLR4/MyD88 [41].
A second explanation for the discrepancy between al-
tered P-glycoprotein function and expression following
LPS treatment is altered trafficking of P-glycoprotein
from intracellular stores to the cell surface. To actively
efflux compounds, P-glycoprotein must be correctly ori-
entated on the plasma membrane. In polarized cells such
as brain capillary endothelium and choroid plexus epi-
thelia, proper routing of intracellular reserves of trans-
porter protein to the plasma membrane on the apical
side is achieved through a series of complex molecular
signaling events. In brain capillaries, intracellular stores
of P-glycoprotein may cycle into and out of the endothe-
lial membranes following exposure to proinflammatory
mediators as a short-term adaptive compensation mech-
anism to cellular stresses [42]. Mechanisms contributing
to trafficking of drug transporter proteins within micro-
glia have not been identified. However, immunohisto-
chemical studies of P-glycoprotein in microglia have
localized the protein to both the plasma and nuclear
membranes, demonstrating that intracellular compart-
ments for the protein do indeed exist [11,43,44] and
might be recruited in response to cellular stress.
The interaction of LPS with microglia at the molecular
level and subsequent signaling pathway activation have
been well described elsewhere [1]. At the cell surface
level, LPS activation of TLR4, scavenger receptors and
NADPH oxidase have all been implicated as initial
events that initiate downstream intracellular signaling
changes in microglia. Inhibition of the scavenger recep-
tors (by fucoidan) and NADPH oxidase (by DPI) in the
present studies did not attenuate the decrease in saquin-
avir accumulation following LPS challenge, whereas a
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Figure 6 TNF-α and nitrite release by HAPI cells following LPS
exposure. Release of TNF-α (A) and nitrite (B) by HAPI cells ino the
medium was measured following 24 hours LPS incubation at 1 to 10
ng/ml. Each data point represents mean ± SE of at least three
separate experiments with three replicates included per experiment;
*P < 0.05, significantly different from untreated control (open bars).
Table 3 Effect of various pathway activators on [3H]
saquinavir accumulation in microglia
Activator Concentration Saquinavir transport (% control)
10 ng/ml LPSa Activator alone
TNF-α 10 ng/ml 73 ± 2 98 ± 6
IL-1β 10 ng/ml 77 ± 2 99 ± 2
DEA NONOate 1 μM 61 ± 2 92 ± 5
DEA NONOate 10 μM 61 ± 2 92 ± 4
DEA NONOate 25 μM 61 ± 2 99 ± 6
ET-1 100 nM 61 ± 3 95 ± 2
PMA 1 μM 58 ± 2 94 ± 4
PCN 1 μM 54 ± 2 99 ± 4
PGE2 1 μM 61 ± 3 103 ± 4
DEA NONOate, 2-(N,N-dimethylamino)-diazenolate-2-oxide; ET-1, endothelin-1;
IL-1β, interleukin-1-beta; TNF-α, tumor necrosis factor-alpha; PMA, phorbol-12-
myristate-13-acetate; PCN, 5-pregnen-3β-ol-20-one-16α-carbonitrile; PGE2,
prostaglandin E2. aIn each separate experiment, 10 ng/ml LPS decreased
saquinavir accumulation significantly (aP < 0.05, statistically significant from
untreated controls).
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TLR-4 neutralizing antibody caused partial attenuation.
By decreasing TLR4 activity to a large extent using micro-
glia from TLR4 deficient mice, full attenuation of the
changes in saquinavir transport in the presence of LPS in
primary microglia was seen. This demonstrates that TLR4
signaling at the cell surface is sufficient to initiate a signal-
ing cascade that affects P-glycoprotein downstream.
In microglia, surface engagement of TLR4 by LPS
leads to activation of multiple intracellular pathways in-
cluding those connected to NF-κβ, AP-1, JAK/STAT,
and multiple protein kinase pathways. Recent studies by
Gibson et al., [45] have shown a role for NF-Κβ in the
regulation of P-gp in a mouse microglia cell line, BV-2.
Interestingly, in this study, LPS at doses of 1 to 500 ng/ml
for 12 hours reduced P-gp expression (mRNA and
protein), and function using the fluorescent P-gp probe
rhodamine 123. In the present study using primary
cultures of mouse microglia, 10 ng/ml LPS decreased
saquinavir accumulation significantly at 6 and 24 hours,
presumably due to increased saquinavir efflux. The
observed decrease in saquinavir accumulation in the
mouse cultures was, however, modest compared to
primary rat cultures, suggesting potential species diffe-
rences. Whether species differences in molecular
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Figure 7 Saquinavir accumulation and inflammatory mediator release following incubation of HAPI cells with a cell permeable NF-κβ
inhibitor. (A) Accumulation of [3H]saquinavir (50 nM) at one hour (37°C) following 24 hours incubation with 10 ng/ml LPS and the NF-κβ
inhibitor SN50 (10 μM) or inactive control peptide SN50I (10 μM). Release of TNF-α (B) and nitrite (C) into the medium following 24 hours
incubation with 10 ng/ml LPS in the presence of the NF-κβ inhibitor SN50 (10 μM) or control peptide SN50I (10 μM) was also measured under
the same experimental conditions. Each data point represents mean ± SE of at least three separate experiments with three replicates included
per experiment; *P < 0.05, significantly different from untreated control cells; #P < 0.05, significantly different from 10 ng/ml LPS and 10 μM
inactive SN50I + LPS.
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mechanisms or specific substrate handling can explain
these discrepancies, remains to be confirmed.
Of all the molecular pathways examined in the present
study, only inhibition of NF-κβ and MEK1/2 reversed
the changes in saquinavir accumulation in microglia
following LPS exposure. Given that several pro-inflam-
matory factors that are known activators of NF-κβ
(for example, TNF-α and IL-1β) were shown to have no
effect, these findings support that NF-κβ is necessary,
but not sufficient to change saquinavir accumulation.
These results are in stark contrast to findings in freshly
isolated rat brain capillaries where LPS also initiates acti-
vation of TLR4, which downstream is connected to
alterations in TNF-α, ET-1, iNOS and PKC acti-
vation, and ultimately results in increased P-glycoprotein
protein expression and consequently function in the
capillaries [42]. This may not be surprising, as the trans-
porter profile in glial cells is quite different compared to
cells of the BBB. Most notably, cultured microglia do
not express significant levels of Mrp2 [12], Bcrp [46] or
mRNA of any of the important SLC uptake transporters
(that is, Slco221a2, 1a5, and Slc22a8) expressed at the
BBB. Given the redundant nature of the LPS response in
microglia (that is, multiple pathways are initiated via
multiple cell surface receptors), we cannot rule out the
possibility that compensatory pathways mask the effects
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Figure 8 Effect of MEK1/2 inhibitor on saquinavir accumulation, TNF-α and nitrite release. Saquinavir accumulation and inflammatory
mediator release was determined following incubation of HAPI cells with a cell permeable MEK1/2 inhibitor U0126 (A). Accumulation of [3H]
saquinavir (50 nM) in the presence and absence of 10 ng/ml LPS and 10 μM U0126 at one hour at 37°C. Release of TNF-α (B) and nitrite (C) into
the medium following 24 hour incubation with 10 ng/ml LPS in the presence of U0126. Each data point represents mean ± SE of at least three
separate experiments with three replicates included per experiment; *P < 0.05, significantly different from untreated control cells.
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of inhibition or activation of a single pathway in our cell
cultures. Further investigations in vivo using knockdown
strategies may be helpful to fully elucidate all the path-
ways that are involved.
In summary, we have demonstrated that exposing
microglial cells to LPS decreases cellular accumulation
of one representative antiretroviral medication. The
ability of LPS to significantly decrease saquinavir accu-
mulation was consistent between microglia derived from
multiple species (rats versus mice), multiple strains
within the same species (Wistar versus Fisher rats), and
multiple cell preparations (cultured cell line versus pri-
mary cells). Using PSC833, a non-immunosuppressive
cyclosporine-A analog and potent P-glycoprotein inhibi-
tor, the decrease in saquinavir accumulation in cultured
microglia was consistent, in part, with an increase in
P-glycoprotein-mediated drug efflux. This increase in
transporter activity and its absence in cells from TLR4-
deficient mice suggest an important role for TLR4 in
microglial P-glycoprotein function and demonstrate its
importance for HIV pharmacotherapy. These results
confirm that the presence of neuroinflammation within
the brain parenchymal compartment can further exacer-
bate the ability of glial cells to actively extrude antiretro-
viral agents, and explains in part why treatment of
neurologically-based HIV strains remains difficult des-
pite our best efforts.
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